open access

Vol 5, No 4 (2009)
Congress abstract / Abstract
Published online: 2009-07-30
Get Citation

“Meeting after ASCO 2009”, 3-4 July 2009, Gdynia

Renata Duchnowska
Onkol. Prak. Klin 2009;5(4):163-179.

open access

Vol 5, No 4 (2009)
Published online: 2009-07-30


Not available


Not available
Get Citation
About this article

“Meeting after ASCO 2009”, 3-4 July 2009, Gdynia


Oncology in Clinical Practice


Vol 5, No 4 (2009)

Article type

Congress abstract / Abstract



Published online


Bibliographic record

Onkol. Prak. Klin 2009;5(4):163-179.


Renata Duchnowska

References (49)
  1. Posner MR, Hershock DM, Blajman CR, et al. TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357(17): 1705–1715.
  2. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008; 359(11): 1116–1127.
  3. Bhide SA, Ahmed M, Rengarajan V, et al. Anemia during sequential induction chemotherapy and chemoradiation for head and neck cancer: the impact of blood transfusion on treatment outcome. Int J Radiat Oncol Biol Phys. 2009; 73(2): 391–398.
  4. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet. 2009; 373(9674): 1532–1542.
  5. Gandara DR, Wakelee H, Calhoun R, et al. Adjuvant chemotherapy of stage I non-small cell lung cancer in North America. J Thorac Oncol. 2007; 2(7 Suppl 3): S125–S127.
  6. Ganti AK, Sahmoun AE, Panwalkar AW, et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol. 2006; 24(1): 59–63.
  7. Mah V, Seligson DB, Li Ai, et al. Aromatase expression predicts survival in women with early-stage non small cell lung cancer. Cancer Res. 2007; 67(21): 10484–10490.
  8. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21): 3543–3551.
  9. Ceppi P, Volante M, Saviozzi S, et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer. 2006; 107(7): 1589–1596.
  10. Liang Z, Zeng X, Gao J, et al. Analysis of EGFR, HER2, and TOP2A gene status and chromosomal polysomy in gastric adenocarcinoma from Chinese patients. BMC Cancer. 2008; 8: 363.
  11. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008; 19(9): 1523–1529.
  12. Moore MJ, Goldstein D, Hamm J, et al. National Cancer Institute of Canada Clinical Trials Group. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007; 25(15): 1960–1966.
  13. Moore M, et al. da Cunha Santos G., Kamel-Reid S. The relationship of K-ras mutations and EGFR copy number with Erlotinib on National Cancer Institute of Canada Trial PA. 3 J Clin Oncol. 2007; 25: 4521.
  14. Castelli R, Porro F, Tarsia P. The heparins and cancer: review of clinical trials and biological properties. Vasc Med. 2004; 9(3): 205–213.
  15. Mousa SA, Petersen LJ. Anti-cancer properties of low-molecular-weight heparin: preclinical evidence. Thromb Haemost. 2009; 102(2): 258–267.
  16. Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer. 2001; 1(2): 104–109.
  17. Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003; 349(3): 247–257.
  18. Kim GP, Colangelo LH, Wieand HS, et al. National Cancer Institute. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study. J Clin Oncol. 2007; 25(7): 767–772.
  19. Sargent D, Marsoni S, Thibodeau SN, et al. Confirmation of deficient mismatch repair (dMMR) as a predictive marker for lack of benefit from 5-FU based chemotherapy in stage II and III colon cancer (CC): a pooled molecular reanalysis of randomized chemotherapy trials. J Clin Oncol. 2008; 26: 180s.
  20. Bertagnolli MM, Niedzwiecki D, Compton CC, et al. Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803. J Clin Oncol. 2009; 27(11): 1814–1821.
  21. Pàez-Ribes M, Allen E, Hudock J, et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell. 2009; 15(3): 220–231.
  22. Ebos JML, Lee CR, Cruz-Munoz W, et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell. 2009; 15(3): 232–239.
  23. Loges S, Mazzone M, Hohensinner P, et al. Silencing or fueling metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell. 2009; 15(3): 167–170.
  24. Byrski T, Huzarski T, Dent R, et al. Response to neoadjuvant therapy with cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2009; 115(2): 359–363.
  25. Garber JE, Richardson A, Harris LN, et al. Neo-adjuvant cisplatin (CDDP) in triple-negative breast cancer (BC). Proceedings San Antonio Breast Cancer Symposium. 2006(abstr. 3074).
  26. Sledge GW, Loehrer PJ, Roth BJ, et al. Cisplatin as first-line therapy for metastatic breast cancer. J Clin Oncol. 1988; 6(12): 1811–1814.
  27. Tassone P, Tagliaferri P, Perricelli A, et al. BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer. 2003; 88(8): 1285–1291.
  28. Schneider BP, Wang M, Radovich M, et al. ECOG 2100. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol. 2008; 26(28): 4672–4678.
  29. Di Le, Gancberg D, Larsimont D, et al. HER2 amplification and topoisomerase II alpha gene aberrations as predictive markers in nodepositive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Clin. Cancer Res. 2002; 8: 1107–1116.
  30. Knoop AS, Knudsen H, Balslev E, et al. Danish Breast Cancer Cooperative Group. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. J Clin Oncol. 2005; 23(30): 7483–7490.
  31. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha and responsiveness of breast cancer to adjuvant chemotherapy. J Natl Cancer Inst. 2009; 101(9): 644–650.
  32. Slamon D, Eiermann W, Robert N, et al. BCIRG 006: 2nd interim analysis phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel with doxorubicin and cyclophosphamide followed by docetaxel and trastuzumab with docetaxel, carboplatin and trastuzumab in HER2 neu positive early breast cancer patients. Breast Cancer Res Treat. 2006; 100: 339–349.
  33. Di Leo A, Larsimont D, Gancberg D, et al. HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide. Ann Oncol. 2001; 12(8): 1081–1089.
  34. Durbecq V, Paesmans M, Cardoso F, et al. Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel. Mol Cancer Ther. 2004; 3(10): 1207–1214.
  35. O'Malley FP, Chia S, Tu D, et al. Topoisomerase II alpha protein overexpression has predictive utility in a randomized trial comparing CMF to CEF in premenopausal women with node positive breast cancer. Breast Cancer Res Treat. 2006; 100: S18.
  36. Di Leo A, Biganzoli L, Claudino W, et al. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Eur J Cancer. 2008; 44(18): 2791–2798.
  37. Harbeck N, Kates RE, Look MP, et al. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424). Cancer Res. 2002; 62(16): 4617–4622.
  38. Vale C, Tierney F, Stewart LA, et al. Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol. 2008; 26: 5802–5812.
  39. Dematteo RP, Ballman KV, Antonescu CR, et al. American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009; 373(9669): 1097–1104.
  40. Dewar AL, Cambareri AC, Zannettino ACW, et al. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib. Blood. 2005; 105(8): 3127–3132.
  41. Kenerson H, Folpe AL, Takayama TK, et al. Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms. Hum Pathol. 2007; 38(9): 1361–1371.
  42. Dewaele B, Wasag B, Cools J, et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res. 2008; 14(18): 5749–5758.
  43. Ryan CW, Mehren Mv, Rankin CJ, et al. Phase II intergroup study of sorafenib (S) in advanced soft tissue sarcomas (STS): SWOG 0505. Journal of Clinical Oncology. 2008; 26(15_suppl): 10532–10532.
  44. Heinrich M, McArthur G, Demetri G, et al. Clinical and Molecular Studies of the Effect of Imatinib on Advanced Aggressive Fibromatosis (desmoid tumor). Journal of Clinical Oncology. 2006; 24(7): 1195–1203.
  45. Sud R, Khorana AA. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model. Thromb Res. 2009; 123 Suppl 4: S18–S21.
  46. Leonard RCF, Mansi JL, Keerie C, et al. Anglo-Celtic Collaborative Oncology Group. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19): 3187–3205.
  47. Aapro MS, Cameron DA, Pettengell R, et al. European Organisation for Research and Treatment of Cancer (EORTC) Granulocyte Colony-Stimulating Factor (G-CSF) Guidelines Working Party. EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphomas and solid tumours. Eur J Cancer. 2006; 42(15): 2433–2453.
  48. Hartsell WF, Scott CB, Bruner DW, et al. Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst. 2005; 97(11): 798–804.
  49. Rades D, Stalpers LJA, Veninga T, et al. Evaluation of five radiation schedules and prognostic factors for metastatic spinal cord compression. J Clin Oncol. 2005; 23(15): 3366–3375.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail: